Original Research
Published on 09 Jun 2022
ACT001 Inhibits TLR4 Signaling by Targeting Co-Receptor MD2 and Attenuates Neuropathic Pain
in Molecular Innate Immunity
Frontiers in Immunology
doi 10.3389/fimmu.2022.873054
- 7,245 views
- 22 citations

